TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00484211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
Study: NCT02045706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker Trainings
Study: NCT03186833

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04755972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of 5% sodium chloride
Description: Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of 8,4% sodium bicarbonate
Description: Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
Study: NCT03186833

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02327442

Intervention type: RADIATION
Intervention: 68Ga-NOTA-NFB
Description: In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.

Intervention type: RADIATION
Intervention: 68Ga-NOTA-NFB
Description: In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.

Intervention type: RADIATION
Intervention: 68Ga-NOTA-NFB
Description: In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
Study: NCT04057261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide Pen Injector [Victoza]
Description: Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo once daily, subcutaneous injection via pre-filled pen.
Study: NCT02281266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: curative resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymalfasin
Description: 1.6mg twice a week, 12 months
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months
Study: NCT04229212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)
Description: In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
Study: NCT02281266

Intervention type: DRUG
Group type: OTHER
Intervention: nucleoside analog (suggest to use entecavir)
Study: NCT04332614

Intervention type: BEHAVIORAL
Intervention: Less-is-better
Description: Email
Study: NCT02281266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleoside analog (suggest to use entecavir)
Study: NCT03987074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
Study: NCT03899142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a human hepatitis B immunoglobulin solution for injection for intramuscular administration
Description: intramuscular administration
Study: NCT04332614

Intervention type: BEHAVIORAL
Intervention: Less-is-better
Description: Email

Intervention type: BEHAVIORAL
Intervention: Less-is-better
Description: Email

Intervention type: BEHAVIORAL
Intervention: Social proof
Description: Email

Intervention type: BEHAVIORAL
Intervention: Endowment / decision staging
Description: Email

Intervention type: BEHAVIORAL
Intervention: Standard email
Description: Email
Study: NCT03602885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual chemotherapy education (CE)
Description: Standard chemo education will given per hospital guideline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chemotherapy education intervention (CEI)
Description: Video, booklet, and website educational materials
Study: NCT04690920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Study: NCT02838901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beet it Beetroot juice
Description: Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beet It Placebo Beetroot juice
Description: Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
Study: NCT04616209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor-derived NK cell infusion
Description: PB103 administrations will be separated by 4-week interval
Study: NCT00823212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS Coronary Stent System
Description: PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT02875223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: Specified dose on specified days
Study: NCT02922842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Study: NCT00149994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
Study: NCT04394273

Intervention type: OTHER
Intervention: Exercise
Description: stabilization exercise

Intervention type: OTHER
Intervention: Exercise
Description: stabilization exercise

Intervention type: OTHER
Intervention: Exercise
Description: stabilization exercise
Study: NCT03484364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENACTS
Description: Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
Study: NCT02069990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT02875223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study: NCT03782051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined phacoemulsification and viscocanalostomy
Description: phacoemulsification with viscocanalostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined phacoemulsification and viscocanalostomy and ologen
Description: phacoemulsification with viscocanalostomy with ologen
Study: NCT02069990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT04375189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Risk Clinic
Description: Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations
Study: NCT04320381

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews
Study: NCT01229059

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lipovenös lipid infusion
Description: Lipid enriched infusions will be applied for 2-6 hours.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lipovenös lipid infusion
Description: Lipid enriched infusions will be applied for 2-6 hours.
Study: NCT00830843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol(3-4 mg/kg/ora)administrated for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
Study: NCT00708643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Silicone Hydrogel Contact Lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study: NCT04345263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
Study: NCT01870440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex Intravitreal Injection (0.7 mg)
Description: Intravitreal Injection
Study: NCT03366441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text messages were sent to an equal number of donors in the SMS group
Study: NCT02047734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule, daily for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule, daily for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozanimod placebo
Description: Oral capsule, daily for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Intramuscular injection, 30 µg, weekly for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a placebo
Description: Intramuscular injection, weekly for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a placebo
Description: Intramuscular injection, weekly for 24 months
Study: NCT02693860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huJ591
Description: Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-J591
Description: Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
Study: NCT03739047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desensitization with flipped spoon
Description: Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: flipped spoon
Description: Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
Study: NCT05497791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial laser stimulation associated with NMES
Description: The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
Study: NCT02572414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Intervention
Description: Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Awareness Control Intervention
Description: Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
Study: NCT04684043

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using drug-eluting stents
Study: NCT02842073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
Study: NCT04284540

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant hypofractionation
Description: 15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive Hypofractionation
Description: 15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
Study: NCT00493896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: The dose for Arixtra is 2.5 mg once daily, subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: The dose for Lovenox is 40 mg once daily, subcutaneously.
Study: NCT01645787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-aminopyridine
Description: 10 mg/twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Crossover study involving one trial with sugar pill (placebo)
Study: NCT05296135

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism-HNSCC™
Description: OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Study: NCT04283968

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation in adults with Atopic Dermatitis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation in adults with Atopic Dermatitis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo fecal transplantation
Description: placebo fecal transplantation
Study: NCT00261781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: Walking on a treadmill 3 times per week for 6 weeks
Study: NCT03987074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
Study: NCT01535092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: 20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT